Cited by 460PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerAutophagy in Disease and Therapy

The DOI matches its Crossref record; 170 of the 171 references it cites were found in a registry or an index.

mTOR signaling in disease

Dazert, Eva, Hall, Michael N·2011·Current Opinion in Cell Biology

DOI 10.1016/j.ceb.2011.09.003

Open this paper in CoChat — free account

Abstract

The target of rapamycin (TOR) is a highly conserved serine/threonine kinase and a central controller of cell growth, metabolism and aging. Mammalian TOR (mTOR) is activated in response to nutrients, growth factors and cellular energy. Dysregulated mTOR signaling has been implicated in major disease. Here we review recent findings on the role of mTOR in cancer, metabolic disorders, neurological diseases, and inflammation.

Integrity signals

Registry

Crossref · 10.1016/j.ceb.2011.09.003

Cites

170 of 170 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma
Garcia-Pedrero, J. M., García‐Carracedo, D., Pinto, C. M., Zapatero, A. H., Rodrigo, J. P., Nieto, C. S., & González, M. V. (2004) · International Journal of Cancer · doi:10.1002/ijc.20711 · Cited by 235
Retracted
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
TOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
Morice, M., Serruys, P. W. J. C., Sousa, J. E., Fajadet, J. C., Hayashi, E. B., Perin, M. A., Colombo, A., Schuler, G. C., Barragan, P. T., Guagliumi, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012843 · Cited by 4,028
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941

Show all 171 references

Sorted by citations

Hepatic mTORC2 Activates Glycolysis and Lipogenesis through Akt, Glucokinase, and SREBP1c
Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., Terracciano, L., Heim, M. H., Rüegg, M. A., & Hall, M. N. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.015 · Cited by 585
Quantitative Phosphoproteomics Reveal mTORC1 Activates de Novo Pyrimidine Synthesis
Robitaille, A. M., Christen, S., Shimobayashi, M., Cornu, M., Fava, L. L., Moes, S., Prescianotto-Baschong, C., Sauer, U., Jenoe, P., & Hall, M. N. (2013) · Science · doi:10.1126/science.1228771 · Cited by 525
Where is mTOR and what is it doing there?
Betz, C., & Hall, M. N. (2013) · The Journal of Cell Biology · doi:10.1083/jcb.201306041 · Cited by 533
SREBPs: metabolic integrators in physiology and metabolism
Jeon, T.-I., & Osborne, T. F. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.10.004 · Cited by 464
Mechanisms of Cardiac and Renal Dysfunction in Patients Dying of Sepsis
Takasu, O., Gaut, J. P., Watanabe, E., To, K. B., Fagley, R. E., Sato, B., Jarman, S., Efimov, I. R., Janks, D., Srivastava, A., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201211-1983oc · Cited by 529
mTOR in aging, metabolism, and cancer
Cornu, M., Albert, V., & Hall, M. N. (2013) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.12.005 · Cited by 455
The Regulation of Cell Size
Lloyd, A. C. (2013) · Cell · doi:10.1016/j.cell.2013.08.053 · Cited by 393
mTORC1 drives HIF-1α and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3
Dodd, K. M., Yang, J., Shen, M. H., Sampson, J. R., & Tee, A. R. (2014) · Oncogene · doi:10.1038/onc.2014.164 · Cited by 404
AMP-activated protein kinase: new regulation, new roles?
Carling, D., Thornton, C., Woods, A., & Sanders, M. J. (2012) · Biochemical Journal · doi:10.1042/bj20120546 · Cited by 390
Recruitment of folliculin to lysosomes supports the amino acid–dependent activation of Rag GTPases
Petit, C. S., Roczniak-Ferguson, A., & Ferguson, S. M. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201307084 · Cited by 355
Oncogenic Roles of the PI3K/AKT/mTOR axis
Aoki, M., & Fujishita, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_6 · Cited by 355
The Search for Antiaging Interventions: From Elixirs to Fasting Regimens
de Cabo, R., Carmona-Gutierrez, D., Bernier, M., Hall, M. N., & Madeo, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.031 · Cited by 345
Self-citation
Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice
Anisimov, V. N., Zabezhinski, M. A., Popovich, I. G., Piskunova, T. S., Semenchenko, A. V., Тындык, М. Л., Yurova, M. N., Rosenfeld, S. V., & Blagosklonny, M. V. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18486 · Cited by 353
Architecture of human mTOR complex 1
Aylett, C. H. S., Sauer, E., Imseng, S., Boehringer, D., Hall, M. N., Ban, N., & Maier, T. (2016) · Science · doi:10.1126/science.aaa3870 · Cited by 344
Self-citation
Increased Mammalian Lifespan and a Segmental and Tissue-Specific Slowing of Aging after Genetic Reduction of mTOR Expression
Wu, J. J., Liu, J., Chen, E. B., Wang, J. J., Cao, L., Narayan, N., Fergusson, M. M., Rovira, I. I., Allen, M., Springer, D. A., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.07.030 · Cited by 307
Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling
Appenzeller‐Herzog, C., & Hall, M. N. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.02.006 · Cited by 324
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 316
Metabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Yu, X., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 313
A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan
Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies
Keppler‐Noreuil, K. M., Parker, V. E. R., Darling, T. N., & Martinez‐Agosto, J. A. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31531 · Cited by 270
Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis
Liu, P., Gan, W., Inuzuka, H., Lazorchak, A. S., Gao, D., Arojo, O., Liu, D., Wan, L., Zhai, B., Yu, Y., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2860 · Cited by 264
Emerging role of autophagy in kidney function, diseases and aging
Huber, T. B., Edelstein, C. L., Hartleben, B., Inoki, K., Jiang, M., Koya, D., Kume, S., Lieberthal, W., Pallet, N., Quiroga, A., et al. (2012) · Autophagy · doi:10.4161/auto.19821 · Cited by 261
Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging.
Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100443 · Cited by 251
Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis
Xu, X., Fan, Z., Kang, L., Han, J., Jiang, C., Zheng, X., Zhu, Z., Jiao, H., Lin, J., Jiang, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64265 · Cited by 249
Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy
Ricos, M. G., Hodgson, B. L., Pippucci, T., Saidin, A., Ong, Y. S., Heron, S. E., Licchetta, L., Bisulli, F., Bayly, M. A., Hughes, J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24547 · Cited by 246
The glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications
Xiao, D., Zeng, L., Kang, Y., Kong, X., Wu, G., & Yin, Y. (2016) · Amino Acids · doi:10.1007/s00726-016-2254-8 · Cited by 246
Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro
Yan, W., Ma, X., Zhao, X., & Zhang, S. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s181939 · Cited by 243
Cancer stem cell metabolism: a potential target for cancer therapy
Deshmukh, A. P., Deshpande, K. S., Arfuso, F., Newsholme, P., & Dharmarajan, A. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0555-x · Cited by 229
mTOR pathway activation drives lung cell senescence and emphysema
Houssaini, A., Breau, M., Kebe, K., Abid, S., Marcos, É., Lipskaia, L., Rideau, D., Parpaleix, A., Huang, J. L., Amsellem, V., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.93203 · Cited by 229
Vitamin D cell signalling in health and disease
Berridge, M. J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.008 · Cited by 215
YB-1: oncoprotein, prognostic marker and therapeutic target?
Lasham, A., Print, C. G., Woolley, A. G., Dunn, S. E., & Braithwaite, A. W. (2012) · Biochemical Journal · doi:10.1042/bj20121323 · Cited by 206
The G Protein-Coupled Taste Receptor T1R1/T1R3 Regulates mTORC1 and Autophagy
Wauson, E., Zaganjor, E., Lee, A.-Y., Guerra, M. L., Ghosh, A. B., Bookout, A. L., Chambers, C. P., Jivan, A., McGlynn, K., Hutchison, M. R., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.08.001 · Cited by 199
Answering the ultimate question “What is the Proximal Cause of Aging?”
Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100525 · Cited by 193
mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions
Showkat, M., Beigh, M. A., & Andrabi, K. I. (2014) · Molecular Biology International · doi:10.1155/2014/686984 · Cited by 196
A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors
Blümcke, I., Aronica, E., Urbach, H., Alexopoulos, A. V., & Gonzalez-Martinez, J. A. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1288-9 · Cited by 178
Mammalian Target of Rapamycin (mTOR) Pathways in Neurological Diseases
Wong, M. (2013) · Biomedical Journal · doi:10.4103/2319-4170.110365 · Cited by 173
Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height
Tatton‐Brown, K., Hanks, S., Ruark, E., Zachariou, A., Duarte, S. D. V., Ramsay, E., Snape, K. M. G., Murray, A., Perdeaux, E. R., Seal, S., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.385 · Cited by 170
Oocyte stage-specific effects of MTOR determine granulosa cell fate and oocyte quality in mice
Guo, J., Zhang, T., Guo, Y., Sun, T., Li, H., Zhang, X., Yin, H. X., Cao, G., Yin, Y., Wang, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800352115 · Cited by 163
Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy
Kim, I., & He, Y. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00175 · Cited by 163
BRAF V600E Mutation Is Associated with mTOR Signaling Activation in Glioneuronal Tumors
Prabowo, A. S., Iyer, A. M., Veersema, T. J., Anink, J. J., Meeteren, A. Y. N. S., Spliet, W. G. M., van Rijen, P. C., Ferrier, C. H., Capper, D., Thom, M., et al. (2013) · Brain Pathology · doi:10.1111/bpa.12081 · Cited by 159
Targeting the Metabolic Microenvironment of Tumors
Bailey, K. M., Wojtkowiak, J. W., Hashim, A. I., & Gillies, R. J. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00004-x · Cited by 157
mTORC1 pathway in DNA damage response
Ma, Y., Vassetzky, Y. S., & Dokudovskaya, S. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.06.011 · Cited by 157
Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21
Cornu, M., Oppliger, W., Albert, V., Robitaille, A. M., Trapani, F., Quagliata, L., Fuhrer, T., Sauer, U., Terracciano, L., & Hall, M. N. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412047111 · Cited by 152
Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR
Akinfiresoye, L. R., & Tizabi, Y. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3153-2 · Cited by 149
MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling
Xu, K., Chen, G., Li, X., Wu, X., Chang, Z., Xu, J., Zhu, Y. T., Yin, P., Liang, X., & Dong, L. (2017) · Scientific Reports · doi:10.1038/srep41718 · Cited by 152
mTORC1 Promotes Denervation-Induced Muscle Atrophy Through a Mechanism Involving the Activation of FoxO and E3 Ubiquitin Ligases
Tang, H., Inoki, K., Lee, M. C., Wright, E., Khuong, A., Khuong, A., Sugiarto, S., Garner, M. S., Paik, J., DePinho, R. A., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004809 · Cited by 145
Cardiac mTOR protects the heart against ischemia-reperfusion injury
Aoyagi, T., Kusakari, Y., Xiao, C.-Y., Inouye, B. T., Takahashi, M., Scherrer‐Crosbie, M., Rosenzweig, A., Hara, K., & Matsui, T. (2012) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00241.2012 · Cited by 144
Geroconversion: irreversible step to cellular senescence
Blagosklonny, M. V. (2014) · Cell Cycle · doi:10.4161/15384101.2014.985507 · Cited by 147
Targeting the mTOR Signaling Network for Alzheimer’s Disease Therapy
Wang, C., Yu, J., Miao, D., Wu, Z., Tan, M., & Tan, L. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8505-8 · Cited by 136
Longevity and aging
Kaeberlein, M. (2013) · F1000Prime Reports · doi:10.12703/p5-5 · Cited by 112
Heat shock factor 1 mediates the longevity conferred by inhibition of TOR and insulin/IGF‐1 signaling pathways in C. elegans
Seo, K., Choi, E. S., Lee, D.-Y., Jeong, D., Jang, S. K., & Lee, S. (2013) · Aging Cell · doi:10.1111/acel.12140 · Cited by 127
mTOR complex 1: a key player in neuroadaptations induced by drugs of abuse
Neasta, J., Barak, S., Hamida, S. B., & Ron, D. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12725 · Cited by 114
A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials
Wong, M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.48 · Cited by 123
Rapamycin-inspired macrocycles with new target specificity
Guo, Z., Hong, S. Y., Wang, J., Rehan, S., Liu, W., Peng, H., Das, M., Li, W., Bhat, S., Peiffer, B., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-018-0187-4 · Cited by 120
Proteasome-dependent Activation of Mammalian Target of Rapamycin Complex 1 (mTORC1) Is Essential for Autophagy Suppression and Muscle Remodeling Following Denervation
Quy, P. N., Kuma, A., Pierre, P., & Mizushima, N. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.399949 · Cited by 120
Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington’s disease
Pryor, W. M., Biagioli, M., Shahani, N., Swarnkar, S., Huang, W., Page, D. T., MacDonald, M. E., & Subramaniam, S. (2014) · Science Signaling · doi:10.1126/scisignal.2005633 · Cited by 111
New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53−/− mice by delaying carcinogenesis
Comas, M., Toshkov, I. A., Kuropatwinski, K. K., Chernova, O. B., Polinsky, A., Blagosklonny, M. V., Gudkov, A. V., & Antoch, M. P. (2012) · Aging · doi:10.18632/aging.100496 · Cited by 117
Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway
Nathan, N. R., Keppler‐Noreuil, K. M., Biesecker, L. G., Moss, J., & Darling, T. N. (2016) · Dermatologic Clinics · doi:10.1016/j.det.2016.07.001 · Cited by 115
p53 induces transcriptional and translational programs to suppress cell proliferation and growth
Loayza-Puch, F., Drost, J., Rooijers, K., Lopes, R., Elkon, R., & Agami, R. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r32 · Cited by 114
Milk’s Role as an Epigenetic Regulator in Health and Disease
Melnik, B. C., & Schmitz, G. (2017) · Diseases · doi:10.3390/diseases5010012 · Cited by 117
Differential Activation of mTOR Complex 1 Signaling in Human Brain with Mild to Severe Alzheimer's Disease
Sun, Y.-X., Ji, X., Mao, X., Xie, L., Jia, J., Galván, V., Greenberg, D. A., & Jin, K. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-131124 · Cited by 119
Milk—A Nutrient System of Mammalian Evolution Promoting mTORC1-Dependent Translation
Melnik, B. C. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160817048 · Cited by 108
Restoration of Corticosteroid Sensitivity in Chronic Obstructive Pulmonary Disease by Inhibition of Mammalian Target of Rapamycin
Mitani, A., Ito, K., Vuppusetty, C., Barnes, P. J., & Mercado, N. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0593oc · Cited by 110
Role of AMPK/mTOR, mitochondria, and ROS in the pathogenesis of endometriosis
Assaf, L., Eid, A. A., & Nassif, J. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120805 · Cited by 119
Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Upregulates Glucose Transporter 1 Transcription via the mTORC1/NF-κB Signaling Pathways
Zhang, J., Jia, L., Lin, W., Yip, Y. L., Lo, K. W., Lau, V. M. Y., Zhu, D., Tsang, C. M., Zhou, Y., Deng, W., et al. (2017) · Journal of Virology · doi:10.1128/jvi.02168-16 · Cited by 105
The 3.2-Å resolution structure of human mTORC2
Scaiola, A., Mangia, F., Imseng, S., Boehringer, D., Berneiser, K., Shimobayashi, M., Stuttfeld, E., Hall, M. N., Ban, N., & Maier, T. (2020) · Science Advances · doi:10.1126/sciadv.abc1251 · Cited by 105
Neuroprotective effects of dietary restriction: Evidence and mechanisms
Pani, G. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.03.004 · Cited by 103
Regulation of TOR by small GTPases
Durán, R. V., & Hall, M. N. (2012) · The EMBO Reports · doi:10.1038/embor.2011.257 · Cited by 102
Molecular signatures of multiple myeloma progression through single cell RNA-Seq
Jang, J. S., Li, Y., Mitra, A., Bi, L., Abyzov, A. S., van Wijnen, A. J., Baughn, L. B., Ness, B. V., Rajkumar, S. V., Kumar, S. K., et al. (2019) · Blood Cancer Journal · doi:10.1038/s41408-018-0160-x · Cited by 100
Xuefu Zhuyu decoction, a traditional Chinese medicine, provides neuroprotection in a rat model of traumatic brain injury via an anti-inflammatory pathway
Xing, Z., Xia, Z., Peng, W., Li, J., Zhang, C., Fu, C., Tang, T., Luo, J., Zou, Y., Fan, R., et al. (2016) · Scientific Reports · doi:10.1038/srep20040 · Cited by 100
Reactive Oxygen Species a Double-Edged Sword for Mesothelioma
Benedetti, S., Nuvoli, B., Catalani, S., & Galati, R. (2015) · Oncotarget · doi:10.18632/oncotarget.4253 · Cited by 97
Melatonin reduced microglial activation and alleviated neuroinflammation induced neuron degeneration in experimental traumatic brain injury: Possible involvement of mTOR pathway
Ding, K., Wang, H., Xu, J., Lu, X., Zhang, L., & Zhu, L. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.06.015 · Cited by 97
TAK ‐228 (formerly MLN 0128), an investigational oral dual TORC 1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia
Ghobrial, I. M., Siegel, D. S. D., Vij, R., Berdeja, J. G., Richardson, P. G. G., Neuwirth, R. B., Patel, C. G., Zohren, F., & Wolf, J. L. (2016) · American Journal of Hematology · doi:10.1002/ajh.24300 · Cited by 100
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin
Xu, J., Pham, C. G., Albanese, S. K., Dong, Y., Oyama, T., Lee, C., Rodrik-Outmezguine, V. S., Yao, Z., Han, S. I., Chen, D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86120 · Cited by 100
4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1
Yang, H., Wang, J., Liu, M., Chen, X., Huang, M., Tan, D., Dong, M.-Q., Wong, C. C. L., Wang, J., Xu, Y., et al. (2016) · Protein & Cell · doi:10.1007/s13238-016-0346-6 · Cited by 96
The role of mTOR signaling pathway in spinal cord injury
Kanno, H., Ozawa, H., Sekiguchi, A., Yamaya, S., Tateda, S., Yahata, K., & Itoi, E. (2012) · Cell Cycle · doi:10.4161/cc.21262 · Cited by 97
Translational Tolerance of Mitochondrial Genes to Metabolic Energy Stress Involves TISU and eIF1-eIF4GI Cooperation in Start Codon Selection
Sinvani, H., Haimov, O., Svitkin, Y. V., Sonenberg, N., Tamarkin-Ben-Harush, A., Viollet, B., & Dikstein, R. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.02.010 · Cited by 99
mTOR, linking metabolism and immunity
Xu, X., Ye, L., Araki, K., & Ahmed, R. (2012) · Seminars in Immunology · doi:10.1016/j.smim.2012.12.005 · Cited by 99
The microRNA-99 family modulates hepatitis B virus replication by promoting IGF-1R/PI3K/Akt/mTOR/ULK1 signaling-induced autophagy
Lin, Y., Deng, W., Pang, J., Kemper, T., Jing Hua, H. U., Yin, J., Zhang, J., & Lu, M. (2016) · Cellular Microbiology · doi:10.1111/cmi.12709 · Cited by 96
Rheb/mTORC1 Signaling Promotes Kidney Fibroblast Activation and Fibrosis
Jiang, L., Xu, L., Mao, J., Li, J., Fang, L., Zhou, Y., Liu, W., He, W., Zhao, A. Z., Yang, J., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012050476 · Cited by 92
Current updates and future perspectives on the management of renal cell carcinoma
Singh, D. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118632 · Cited by 91
Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells
Leontieva, O. V., Lenzo, F. L., Demidenko, Z. N., & Blagosklonny, M. V. (2012) · Cell Cycle · doi:10.4161/cc.22937 · Cited by 92
The histone H3 lysine 56 acetylation pathway is regulated by target of rapamycin (TOR) signaling and functions directly in ribosomal RNA biogenesis
Chen, H., Fan, M., Pfeffer, L. M., & Laribee, R. N. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks345 · Cited by 94
mTOR Signaling in T Cell Immunity and Autoimmunity
Liu, Y., Zhang, D., & Liu, X. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2014.933957 · Cited by 94
Molecular damage in cancer: an argument for mTOR-driven aging
Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100422 · Cited by 88
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia
Simioni, C., Neri, L. M., Tabellini, G., Ricci, F., Bressanin, D., Chiarini, F., Evangelisti, C., Cani, A., Tazzari, P. L., Melchionda, F., et al. (2012) · Leukemia · doi:10.1038/leu.2012.136 · Cited by 87
Differential Contribution of Insulin and Amino Acids to the mTORC1-Autophagy Pathway in the Liver and Muscle
Naito, T., Kuma, A., & Mizushima, N. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.456228 · Cited by 88
Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin
Huang, Y., Hu, J., Zheng, J., Li, J., Wei, T., Zheng, Z., & Chen, Y. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-48 · Cited by 86
Coordination of the leucine-sensing Rag GTPase cycle by leucyl-tRNA synthetase in the mTORC1 signaling pathway
Lee, M., Kim, J. H., Yoon, I., Lee, C., Fallahi‐Sichani, M., Kang, J. S., Kang, J., Guo, M., Lee, K. Y., Han, G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1801287115 · Cited by 90
Regulation of Blood–Testis Barrier (BTB) Dynamics during Spermatogenesis via the “Yin” and “Yang” Effects of Mammalian Target of Rapamycin Complex 1 (mTORC1) and mTORC2
Mok, K., Mruk, D. D., & Cheng, C. Y. (2013) · International review of cytology · doi:10.1016/b978-0-12-407704-1.00006-3 · Cited by 84
Suppression of replicative senescence by rapamycin in rodent embryonic cells
Pospelova, T. V., Leontieva, O. V., Bykova, T. V., Zubova, S. G., Pospelov, V. A., & Blagosklonny, M. V. (2012) · Cell Cycle · doi:10.4161/cc.20882 · Cited by 86
Rapalogs in cancer prevention
Blagosklonny, M. V. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.22859 · Cited by 83
mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics
Zhang, H., Xiao, X., Pan, Z., & Dokudovskaya, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02493-4 · Cited by 94
Inhibition of mTOR pathway restrains astrocyte proliferation, migration and production of inflammatory mediators after oxygen–glucose deprivation and reoxygenation
Li, C., Li, X., Liu, S.-F., Qu, W., Wang, W., & Tian, D. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.03.001 · Cited by 86
Rapamycin extends life- and health span because it slows aging
Blagosklonny, M. V. (2013) · Aging · doi:10.18632/aging.100591 · Cited by 82
Glutaminolysis feeds mTORC1
Durán, R. V., & Hall, M. N. (2012) · Cell Cycle · doi:10.4161/cc.22632 · Cited by 77
Hormesis does not make sense except in the light of TOR-driven aging
Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100411 · Cited by 83
Architecture of the human mTORC2 core complex
Stuttfeld, E., Aylett, C. H. S., Imseng, S., Boehringer, D., Scaiola, A., Sauer, E., Hall, M. N., Maier, T., & Ban, N. (2018) · eLife · doi:10.7554/elife.33101 · Cited by 86
miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer
Feng, W., Liu, Y., Guo, Y., An, X., Wang, G., Xue, X., & Lu, Z. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-81 · Cited by 77
Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML
Herschbein, L., & Liesveld, J. L. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.11.006 · Cited by 76

Authors: Dazert, E., & Hall, M. N.
Affiliations: University of Basel (CH)
ORCID: Dazert, Eva
Hall, Michael N
Venue: Current Opinion in Cell Biology
Publisher: Elsevier BV
Published: 2011-12
Volume: 23
Issue: 6
Pages: 744-755
ISSN: 0955-0674 (ISSN-L)
DOI: 10.1016/j.ceb.2011.09.003
OpenAlex: W2076457380
Cited by: 460
References: 171
Citations by year: 2026: 10 · 2025: 13 · 2024: 12 · 2023: 18 · 2022: 24 · 2021: 26 · 2020: 18 · 2019: 19 · 2018: 38 · 2017: 34 · 2016: 34 · 2015: 38 · 2014: 65 · 2013: 51 · 2012: 54
FWCI: 5.11
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Current Opinion in Cell Biology (publishedVersion)
PubMed (publishedVersion)
Funders: Louis-Jeantet Foundation
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
Keywords: mTOR signaling, mammalian target of rapamycin, serine/threonine kinase, cell growth regulation, metabolism, aging, cancer, metabolic disorders, neurological disorders, inflammation, nutrient sensing
MeSH terms: Animals, Disease Models, Animal, Humans, Mammals, Neoplasms, Signal Transduction, Cell Proliferation, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

mTOR signaling in disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks